Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Mont...(nt assets under marketable securities on...),Health

Date:1/31/2008

nt assets under marketable securities on the company's balance sheet. Given the failed auctions, the company's ARS are illiquid until there is a successful auction for them. Accordingly, the entire amount of such remaining ARS has been reclassified from current to non-current assets on the company's balance sheet.

If uncertainties in the credit and capital markets continue, these markets deteriorate further or the company experiences any additional ratings downgrades on any investments in its portfolio (including on ARS), the company may incur additional impairments to its investment portfolio, which could negatively affect the company's financial condition, cash flow and reported earnings. The company believes that based on the company's current cash, cash equivalents and marketable securities balances of $2.2 billion at December 31, 2007 and expected operating cash flows, the current lack of liquidity in the credit and capital markets will not have a material impact on the company's liquidity, cash flow, financial flexibility or its ability to fund its operations, including the dividend.

For information on specified items, see Appendix 2. Details reconciling these non-GAAP amounts with GAAP amounts including specified items are provided in Appendix 1 attached and in supplemental materials available on the company's website.

PHARMACEUTICALS

Worldwide pharmaceutical sales increased 39% to $4.4 billion in the fourth quarter of 2007, including a 5% favorable foreign exchange impact, compared to the same period in 2006.

U.S. pharmaceutical sales increased 65% to $2.5 billion in the fourth quarter of 2007 compared to the same period in 2006, primarily due to increased PLAVIX(R) sales, as well as the continued growth of ABILIFY(R), REYATAZ(R), the SUSTIVA(R) Franchise and ERBITUX(R), and sales of newer products ORENCIA(R), BARACLUDE(R), SPRYCEL(TM) and IXEMPRA(TM).

International pharmaceutical sales increased 16%, including a 10%
'/>"/>

SOURCE Bristol-Myers Squibb Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Related medicine news :

1. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
2. Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors
3. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
4. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
5. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
6. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
7. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
8. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
9. Bristol-Myers Squibb Announces Dividend
10. P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company
11. First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II